Entera Bio Presents Phase 2 Data Supporting EB613 Benefits In Women With Osteoporosis At ASBMR 2026 Annual Meeting

Entera Bio Ltd. presented post-hoc Phase 2 data at the ASBMR 2026 Annual Meeting, indicating that EB613 shows greater bone mineral density gains in postmenopausal women with osteoporosis compared to those with osteopenia. The findings support the potential benefits of EB613 for women at high risk for fractures, aligning with the study population for Entera's upcoming Phase 3 study. The presentations included a Plenary Poster and a Late-breaking Poster, highlighting the company's advancements in oral peptide development.